Description: Thiogenesis Therapeutics, Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of a range of unmet genetic and central nervous system diseases. Its lead product candidate under development is TTI-0102, a prodrug consisting of cysteamine and pantetheine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke. The company is headquartered in Toronto, Canada.
Home Page: www.thiogenesis.com
TTI Technical Analysis
4 King Street West
Toronto,
ON
M5H 1B6
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Patrice P. Rioux M.D., Ph.D. | CEO & Director |
| Ms. Mary Jo Bagger | Consultant for Clinical Operations |
| Mr. Brook G. Riggins C.F.A. | CFO, Sec. & Director |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.9014 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |